Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Employment prospects good for most cancer survivors -- but not all

22.03.2005


Only one of five cancer survivors surveyed in a Penn State study were disabled or out of work four years after treatment, but a minority suffered lasting effects that prevented them from working.



Dr. Pamela Farley Short, professor of health policy and administration and demography who led the study, says, "One of the reassuring findings from this study is that encouraging people to get mammograms to detect breast cancer and PSA tests to check for prostate cancer has clearly had a positive effect. People diagnosed early with these cancers usually have a good quality of life four to five years after treatment -- including being fully employed.

"However, there is a minority of cancer survivors who have on-going problems and the challenge is to help them with a comprehensive range of clinical and supportive services aimed at better management of symptoms, rehabilitation and accommodation of disabilities," she adds.


Short, who is a member of the U.S. Institute of Medicine’s Cancer Survivorship Committee, notes that there are, currently, about 10 million U.S. cancer survivors. So, the minority who survive but have continuing problems represent about 2 million people.

The study, "Employment Pathways in a Large Cohort of Adult Cancer Survivors," is detailed in the current issue of the journal, Cancer. Short’s co-authors are Dr. Joseph J. Vasey, research associate in Penn State’s Center for Health Care and Policy Research, and Dr. Kaan Tunceli, Short’s former doctoral student who is now at the Center for Health Services Research, Henry Ford Health System, Detroit, Michigan.

In the study, 1433 men and women, ages 25 to 62 who were working at the time of their cancer diagnosis, were interviewed about their employment and disability status two to five years later. All types of cancer survivors were included, except for those with common skin cancers and most patients diagnosed at an advanced stage.

The researchers found that similar numbers of men and women stopped working during cancer treatment (41 percent of men and 39 percent of women) and most of those who returned to work did so during the first year after treatment. The rate of return to work after four years was 84 percent.

One worker out of eight quit work because of cancer within four years of being diagnosed, with women more likely to quit than men. The highest rates of quitting were among those with blood, central nervous system and head and neck cancers. The lowest rates of quitting were among survivors of uterine, female breast, prostate and thyroid cancers.

Short notes, "Today, most cancer patients can be very hopeful for a good outcome and a continued ability to work. But survivors who experience lasting problems post-treatment should not hesitate to tell their physicians when they have difficulty at work. " The study was supported by a grant from the National Cancer Institute.

Barbara Hale | EurekAlert!
Further information:
http://www.psu.edu

More articles from Health and Medicine:

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

nachricht Vanishing capillaries
23.03.2017 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

NASA examines Peru's deadly rainfall

24.03.2017 | Earth Sciences

What does congenital Zika syndrome look like?

24.03.2017 | Health and Medicine

Steep rise of the Bernese Alps

24.03.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>